PTCT
Price
$46.74
Change
-$1.63 (-3.37%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
3.69B
21 days until earnings call
RCUS
Price
$7.18
Change
-$0.71 (-9.00%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
835.09M
40 days until earnings call
Ad is loading...

PTCT vs RCUS

Header iconPTCT vs RCUS Comparison
Open Charts PTCT vs RCUSBanner chart's image
PTC Therapeutics
Price$46.74
Change-$1.63 (-3.37%)
Volume$16.55K
Capitalization3.69B
Arcus Biosciences
Price$7.18
Change-$0.71 (-9.00%)
Volume$16.64K
Capitalization835.09M
PTCT vs RCUS Comparison Chart
Loading...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTCT vs. RCUS commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTCT is a Hold and RCUS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (PTCT: $48.37 vs. RCUS: $7.89)
Brand notoriety: PTCT and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTCT: 111% vs. RCUS: 66%
Market capitalization -- PTCT: $3.69B vs. RCUS: $758.88M
PTCT [@Biotechnology] is valued at $3.69B. RCUS’s [@Biotechnology] market capitalization is $758.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTCT’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • PTCT’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, PTCT is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTCT’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 4 bullish TA indicator(s).

  • PTCT’s TA Score: 5 bullish, 4 bearish.
  • RCUS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both PTCT and RCUS are a good buy in the short-term.

Price Growth

PTCT (@Biotechnology) experienced а -12.55% price change this week, while RCUS (@Biotechnology) price change was -4.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

PTCT is expected to report earnings on Apr 24, 2025.

RCUS is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($3.69B) has a higher market cap than RCUS($835M). PTCT YTD gains are higher at: 7.156 vs. RCUS (-47.011). PTCT has higher annual earnings (EBITDA): -120.46M vs. RCUS (-269M). PTCT has more cash in the bank: 1.14B vs. RCUS (978M). RCUS has less debt than PTCT: RCUS (60M) vs PTCT (2.47B). PTCT has higher revenues than RCUS: PTCT (807M) vs RCUS (258M).
PTCTRCUSPTCT / RCUS
Capitalization3.69B835M442%
EBITDA-120.46M-269M45%
Gain YTD7.156-47.011-15%
P/E RatioN/AN/A-
Revenue807M258M313%
Total Cash1.14B978M117%
Total Debt2.47B60M4,118%
FUNDAMENTALS RATINGS
PTCT vs RCUS: Fundamental Ratings
PTCT
RCUS
OUTLOOK RATING
1..100
5653
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4594
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for PTCT (99) in the Biotechnology industry. This means that RCUS’s stock grew somewhat faster than PTCT’s over the last 12 months.

RCUS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PTCT (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to PTCT’s over the last 12 months.

RCUS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as PTCT (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for RCUS (94) in the Pharmaceuticals Major industry. This means that PTCT’s stock grew somewhat faster than RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as PTCT (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to PTCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTCTRCUS
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 18 days ago
76%
Bullish Trend 29 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DODWX14.640.06
+0.41%
Dodge & Cox Global Stock I
REGRX16.700.03
+0.18%
Russell Inv Emerging Markets R6
PABAX15.62N/A
N/A
Putnam Dynamic Asset Allocation Bal A
SGARX23.11N/A
N/A
Virtus SGA Global Growth R6
LYFAX12.70N/A
N/A
AlphaCentric Life Sciences & Hlthcare A

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ACLX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+2.33%
ACLX - RCUS
42%
Loosely correlated
+10.76%
APGE - RCUS
42%
Loosely correlated
+6.23%
ATXS - RCUS
41%
Loosely correlated
+2.22%
IDYA - RCUS
40%
Loosely correlated
+10.70%
ITOS - RCUS
40%
Loosely correlated
+2.49%
More